Boston Scientific Corp. Hits New 52-Week Low at $47.35

Boston Scientific Corp. has reached a significant milestone by touching a new 52-week low of USD 47.35 on June 1, 2026. This decline marks a notable downturn for the company, which has experienced a 1-year performance drop of 38.03%. In contrast, the S&P 500 has shown a robust performance increase of 28.56% during the same period, highlighting the challenges faced by Boston Scientific in the current market environment. With a market capitalization of USD 121,935 million, Boston Scientific operates within the retailing industry as a large-cap entity. The company's price-to-earnings (P/E) ratio stands at 36.00, indicating how investors value its earnings relative to its stock price. Additionally, the company maintains a debt-to-equity ratio of 0.39, suggesting a moderate level of leverage. The return on equity is reported at 13.88%, while the price-to-book ratio is 5.03. As Boston Scientific navigates these market dynamics, the recent low reflects broader trends impacting its stock performance.